AVXL

$4.55

Post-MarketAs of Mar 17, 8:00 PM UTC

Anavex Life Sciences Corp.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.55
Potential Upside
5%
Whystock Fair Value$4.78
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett s...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$421.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-33.63%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
20.81

Recent News

MarketBeat
Mar 5, 2026

Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference

Anavex Life Sciences (NASDAQ:AVXL) CEO Christopher Missling presented an update on the company’s central nervous system pipeline at the firm’s 46th Annual Healthcare Conference, highlighting late-stage data for its oral Alzheimer’s candidate blarcamesine, upcoming regulatory and clinical milestones,

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 13, 2026

3 Promising Penny Stocks With At Least $200M Market Cap

As the United States stock market kicks off February with a strong start, major indexes like the Dow Jones and S&P 500 have shown impressive gains. In this context of optimism, penny stocks—often overlooked due to their smaller size or younger age—can present unique opportunities for investors. Despite the term's dated connotation, these stocks can still offer substantial value when supported by robust financials. This article will explore three such promising penny stocks that stand out for...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 12, 2026

Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 12, 2026

Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?

Here is how Anavex Life Sciences (AVXL) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Feb 10, 2026

High Growth Tech Stocks In US With Promising Potential

As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average rising by 515 points and the S&P 500 nearing a record high, reflecting positive market sentiment despite recent economic uncertainties such as delayed jobs data due to a government shutdown. In this environment of heightened optimism and volatility, identifying high growth tech stocks with promising potential requires focusing on companies that demonstrate strong innovation capabilities and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.